Drugmakers pause or review UK investments amid dispute over rebates and support for vaccines
Pharmaceutical companies including AstraZeneca, Eli Lilly and Merck have signalled pauses or reviews of UK projects as industry objections to higher NHS medicine rebates and cuts to vaccine support surface